Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 33Not yet recruiting 26Completed 20Unknown 12Active not recruiting 4Withdrawn 3Terminated 3Enrolling by invitation 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Brain Neoplasms 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × OTHER × irinotecan sucrosofate × Clear all
NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Washington University School of Medicine

Phase 2 Withdrawn
BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT05251038 2023-05-11

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Hoosier Cancer Research Network

Phase 1/2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT03739801 2020-03-27

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

University of Southern California

Phase 1/2 Withdrawn
Gastrointestinal

Locally Advanced Unresectable Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡